Generic ActoPlus Met XR Availability

See also: Generic ActoPlus Met

ActoPlus Met XR is a brand name of metformin/pioglitazone, approved by the FDA in the following formulation(s):

ACTOPLUS MET XR (metformin hydrochloride; pioglitazone hydrochloride - tablet, extended release;oral)

  • Manufacturer: TAKEDA PHARMS USA
    Approval date: May 12, 2009
    Strength(s): 1GM;EQ 15MG BASE, 1GM;EQ 30MG BASE [RLD]

Has a generic version of ActoPlus Met XR been approved?

No. There is currently no therapeutically equivalent version of ActoPlus Met XR available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ActoPlus Met XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical composition
    Patent 5,965,584
    Issued: October 12, 1999
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:
    • June 19, 2016
      ✓ 
      Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
      ✓ 
      Drug product
  • Controlled release oral tablet having a unitary core
    Patent 6,099,859
    Issued: August 8, 2000
    Inventor(s): Cheng; Xiu Xiu & Chen; Chih-Ming & Jan; Steve & Chou; Joseph
    Assignee(s): Andrx Pharmaceuticals, Inc.
    A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.
    Patent expiration dates:
    • March 20, 2018
      ✓ 
      Drug product
  • Pharmaceutical composition
    Patent 6,166,042
    Issued: December 26, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:
    • June 19, 2016
      ✓ 
      Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
  • Pharmaceutical composition
    Patent 6,166,043
    Issued: December 26, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:
    • June 19, 2016
      ✓ 
      Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
  • Pharmaceutical composition
    Patent 6,172,090
    Issued: January 9, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:
    • June 19, 2016
      ✓ 
      Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
  • Controlled release oral tablet having a unitary core
    Patent 6,495,162
    Issued: December 17, 2002
    Inventor(s): Xiu Xiu; Cheng & Chih-Ming; Chen & Steve; Jan & Joseph; Chou
    Assignee(s): Andrx Pharmaceuticals, Inc.
    A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.
    Patent expiration dates:
    • March 20, 2018
      ✓ 
      Drug product
  • Methods for treating diabetes via administration of controlled release metformin
    Patent 6,790,459
    Issued: September 14, 2004
    Inventor(s): Xiu Xiu; Cheng & Chih-Ming; Chen & Steve; Jan & Joseph; Chou
    Assignee(s): Andrx Labs, LLC
    A method for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at a 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.
    Patent expiration dates:
    • March 17, 2021
      ✓ 
      Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
  • Controlled release metformin compositions
    Patent 6,866,866
    Issued: March 15, 2005
    Inventor(s): Chen; Chih-Ming & Cheng; Xiu-Xiu & Jan; Steve & Chou; Joseph
    Assignee(s): Andrx Labs, LLC
    A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.
    Patent expiration dates:
    • March 17, 2021
      ✓ 
      Drug product
  • Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
    Patent 7,785,627
    Issued: August 31, 2010
    Inventor(s): Kositprapa; Unchalee & Goldfarb; Robert I. & Cardinal; John & Nangia; Avinash
    Assignee(s): Watson Pharmaceuticals, Inc.
    A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.
    Patent expiration dates:
    • July 31, 2026
      ✓ 
      Drug product
  • Controlled release metformin formulations
    Patent 7,919,116
    Issued: April 5, 2011
    Inventor(s): Chen; Chih-Ming & Cheng; Xiu Xiu & Jan; Steve & Chou; Joseph
    Assignee(s): Andrx Labs, LLC
    Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.
    Patent expiration dates:
    • March 20, 2018
      ✓ 
      Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
    • March 20, 2018
      ✓ 
      Patent use: TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL
  • Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
    Patent 7,959,946
    Issued: June 14, 2011
    Inventor(s): Kositprapa; Unchalee & Goldfarb; Robert I. & Cardinal; John R. & Nangia; Avinash
    Assignee(s): Watson Pharmaceuticals, Inc.
    A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.
    Patent expiration dates:
    • July 31, 2026
      ✓ 
      Drug product
  • Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
    Patent 8,470,368
    Issued: June 25, 2013
    Assignee(s): Watson Pharmaceuticals, Inc.
    A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.
    Patent expiration dates:
    • September 19, 2023
      ✓ 
      Drug product
  • Controlled release metformin formulations
    Patent 8,475,841
    Issued: July 2, 2013
    Assignee(s): Andrx Labs, LLC
    Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.
    Patent expiration dates:
    • March 20, 2018
      ✓ 
      Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
  • Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
    Patent 8,668,931
    Issued: March 11, 2014
    Assignee(s): Actavis, Inc.
    A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.
    Patent expiration dates:
    • September 19, 2023
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)